en · de · es
sr9009-notes.peptides1004.com › Info › Sr9009 Background And Mechanism — Quick Reference

Sr9009 Background And Mechanism — Quick Reference

By Editorial Desk · published 2026-02-06 · last reviewed 2026-02-21 · Info

circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-02-21 and is reviewed periodically as new material appears.

SR9009 Background and Mechanism

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Analytical Detection and Regulatory Status

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small-molecule REV-ERB agonistNot a hormone or natural product
Primary targetsREV-ERBα and REV-ERBβNuclear receptors involved in circadian and metabolic regulation
AppearanceWhite to off-white solidTypical for purified research samples
SolubilitySoluble in DMSO and ethanol; low water solubilityLaboratory solubility depends on solvent and purity
Common synonymsSR9009; StenabolicStenabolic is a colloquial name, not a formal chemical name

SR9009 Identity and Mechanism

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

Related pages on this site

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Background and Mechanism of SR9009

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

Background from the literature

=== Plasmapheresis and IVIG === If the myasthenia is serious (myasthenic crisis), plasmapheresis can be used to remove the putative antibodies from the circulation. Also, intravenous immunoglobulins (IVIGs) can be used to bind the circulating antibodies. Both of these treatments have relatively short-lived benefits, typically measured in weeks, and often are associated with high costs, which make them prohibitive; they are generally reserved for when MG requires hospitalization.

1993/29) Income Support (General) Amendment Regulations 1993 (S.I. 1993/30) Motor Vehicles (Wearing of Seat Belts by Children in Front Seats) Regulations 1993 (S.I. 1993/31) Food Protection (Emergency Prohibitions) (Radioactivity in Sheep) (Wales) (Partial Revocation) Order 1993 (S.I. 1993/32) Food Protection (Emergency Prohibitions) (Radioactivity in Sheep) (England) (Partial Revocation) Order 1993 (S.I. 1993/33) North West London Mental Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/34) Road Traffic Regulation Act 1984 (Amendment) Order 1993 (S.I. 1993/35) Local Authorities (Discretionary Expenditure) (Relevant Population) Regulations 1993 (S.I. 1993/40) Local Authorities (Discretionary Expenditure Limits) Order 1993 (S.I. 1993/41) Control of Pollution (Anglers' Lead Weights) (Amendment) Regulations 1993 (S.I. 1993/49) Gipsy Encampments (London Borough of Bromley) Order 1993 (S.I. 1993/50) Licensed Betting Offices (Amendment) Regulations 1993 (S.I. 1993/51) Combined Probation Areas (Powys) Order 1993 (S.I. 1993/52) National Rivers Authority (Anglian Region) (Reconstitution of the Alford Drainage Board) Order 1992 S.I. 1993/53) National Rivers Authority (Anglian Region) (Reconstruction of the North East Lindsey Internal Drainage Board) Order 1992 S.I. 1993/54) National Rivers Authority (Anglian Region) (Reconstitution of the Louth Drainage Board) Order 1992 S.I. 1993/55) Education (Higher Education Corporations) (Wales) (No. 3) Order 1993 (S.I. 1993/56) Friendly Societies (Group Schemes) Regulations 1993 (S.I.

Quantum wires, which confine electrons or holes in two spatial dimensions and allow free propagation in the third. Quantum wells, which confine electrons or holes in one dimension and allow free propagation in two dimensions.

==== João Rouxinhol's lie ==== João Rouxinhol, one of the inspectors of the first investigation team of the PJ stated in court in 2012 that he lied to the press in 2005 when he accused Mendonça's family of having hidden the fact that Mendonça suffered from epilepsy. When questioned by the press about the following statement given in court he said that it doesn't match with a lie:"When I said it, I said it, the statement not being true. What I said about only knowing in 2005 about the epilepsy is not factually true, I gave that interview thrilled by some revolt that I felt for what was being said against our investigation team."The inspector received a light punishment of 25 days of suspension, replaced by loss of salary in retirement pension. João Rouxinhol also said that because of "forgetfulness" he did not listen to the witness Alcina Dias. Other crucial witnesses were heard years after the disappearance and by another investigation team. One of them a merchant that said he saw Alcina Dias with a boy.

α-Iron is a fairly soft metal that can dissolve only a small concentration of carbon (no more than 0.021% by mass at 910 °C). Austenite (γ-iron) is similarly soft and metallic but can dissolve considerably more carbon (as much as 2.04% by mass at 1146 °C). This form of iron is used in the type of stainless steel used for making cutlery, and hospital and food-service equipment. Commercially available iron is classified based on purity and the abundance of additives. Pig iron has 3.5–4.5% carbon and contains varying amounts of contaminants such as sulfur, silicon and phosphorus. Pig iron is not a saleable product, but rather an intermediate step in the production of cast iron and steel. The reduction of contaminants in pig iron that negatively affect material properties, such as sulfur and phosphorus, yields cast iron containing 2–4% carbon, 1–6% silicon, and small amounts of manganese. Pig iron has a melting point in the range of 1420–1470 K, which is lower than either of its two main components, and makes it the first product to be melted when carbon and iron are heated together. Its mechanical properties vary greatly and depend on the form the carbon takes in the alloy. "White" cast irons contain their carbon in the form of cementite, or iron carbide (Fe3C). This hard, brittle compound dominates the mechanical properties of white cast irons, rendering them hard, but unresistant to shock. The broken surface of a white cast iron is full of fine facets of the broken iron carbide, a very pale, silvery, shiny material, hence the appellation.

Sources: en.wikipedia.org

Further detail

== Clinical significance == Toxic vacuolation is associated with sepsis, particularly when accompanied by toxic granulation. The finding is also associated with bacterial infection, alcohol toxicity, liver failure, and treatment with granulocyte colony-stimulating factor, a cytokine drug used to increase the absolute neutrophil count in patients with neutropenia. The formation of toxic vacuoles represents increased phagocytic activity, which is stimulated by the release of cytokines in response to inflammation or tissue injury. Toxic vacuolation frequently occurs in conjunction with toxic granulation and Döhle bodies in inflammatory states, and these findings are collectively referred to as toxic changes. Neutrophilia and left shift (the presence of immature neutrophil precursors such as band neutrophils and metamyelocytes in the peripheral blood) often accompany toxic changes, as these phenomena also occur in response to inflammation. It has been suggested that neutrophil vacuoles not be labelled "toxic vacuoles" unless they are accompanied by other toxic changes, as vacuolation can occur in other conditions.

Major League Baseball's drug policy prohibits players from using, possessing, selling, facilitating the sale of, distributing, or facilitating the distribution of any Drug of Abuse and/or Steroid. Any and all drugs or substances listed under Schedule II of the Controlled Substances Act are considered drugs of abuse covered by the Program. Players who require prescription medication can still use it with a "Therapeutic Use Exemption" granted by MLB. In December 2019, MLB removed cannabinoids and added cocaine and opiates to its list of Drugs of Abuse. However, players were told that they could still be suspended for possessing or selling cannabis, or driving under the influence of cannabis.

=== Advocacy groups === Even the Score, a coalition of women's groups brought together by a Sprout consultant, actively campaigned for the approval of flibanserin. The campaign emphasized that several approved treatments for male sexual dysfunction exist, while no such treatment for women was available. The group successfully obtained letters of support from the President of the National Organization for Women, the editor of the Journal of Sexual Medicine, and several members of Congress. Other organizations supporting the approval of flibanserin included the National Council of Women's Organizations, the Black Women's Health Imperative, the Association of Reproductive Health Professionals, National Consumers League, and the American Sexual Health Association. The approval was opposed by the National Women's Health Network, the National Center for Health Research and Our Bodies Ourselves. A representative of PharmedOut said "To approve this drug will set the worst kind of precedent—that companies that spend enough money can force the FDA to approve useless or dangerous drugs." An editorial in JAMA noted that, "Although flibanserin is not the first product to be supported by a consumer advocacy group in turn supported by pharmaceutical manufacturers, claims of gender bias regarding the FDA's regulation have been particularly noteworthy, as have the extent of advocacy efforts ranging from social media campaigns to letters from members of Congress".

Xylose reductase catalyses the initial reaction in the xylose utilization pathway. The enzyme can use nicotinamide adenine dinucleotide (NADH) or nicotinamide adenine dinucleotide phosphate (NADPH) as its cofactor.

There are differences in the regulation for the release of GMOs between countries, with some of the most marked differences occurring between the US and Europe. Regulation varies in a given country depending on the intended use of the products of the genetic engineering. For example, a crop not intended for food use is generally not reviewed by authorities responsible for food safety. Some nations have banned the release of GMOs or restricted their use, and others permit them with widely differing degrees of regulation. In 2016, thirty eight countries officially ban or prohibit the cultivation of GMOs and nine (Algeria, Bhutan, Kenya, Kyrgyzstan, Madagascar, Peru, Russia, Venezuela and Zimbabwe) ban their importation. Most countries that do not allow GMO cultivation do permit research using GMOs. Despite regulation, illegal releases have sometimes occurred, due to weakness of enforcement. The European Union (EU) differentiates between approval for cultivation within the EU and approval for import and processing. While only a few GMOs have been approved for cultivation in the EU a number of GMOs have been approved for import and processing. The cultivation of GMOs has triggered a debate about the market for GMOs in Europe. Depending on the coexistence regulations, incentives for cultivation of GM crops differ. The US policy does not focus on the process as much as other countries, looks at verifiable scientific risks and uses the concept of substantial equivalence. Whether gene edited organisms should be regulated the same as genetically modified organism is debated.

Sources: en.wikipedia.org

Supporting material

American banker and amateur ethnomycologist R. Gordon Wasson and his wife, Valentina P. Wasson, a physician, studied the ritual use of psychoactive mushrooms by the native population in the Mazatec village Huautla de Jiménez, Mexico. In 1957, Wasson described the psychedelic visions he experienced during these rituals in "Seeking the Magic Mushroom", an article published in the American weekly Life magazine. Later the same year they were accompanied on a follow-up expedition by French mycologist Roger Heim, who identified several of the mushrooms as Psilocybe species. Heim cultivated the mushrooms in France and sent samples for analysis to Albert Hofmann, a chemist employed by the Swiss pharmaceutical company Sandoz. Hofmann—who had synthesized lysergic acid diethylamide (LSD) in 1938—led a research group that isolated and identified the psychoactive alkaloids psilocybin and psilocin from Psilocybe mexicana, publishing their results in 1958. The team was aided in the discovery process by Hofmann's willingness to ingest mushroom extracts to help verify the presence of the active compounds. Next, Hofmann's team synthesized several structural analogs of these compounds to examine how these structural changes affect psychoactivity. This research led to the development of ethocybin and CZ-74. Because these compounds' physiological effects last only about three and a half hours (about half as long as psilocybin's), they proved more manageable for use in psycholytic therapy.

Euphoria season 3 was met with a mixed response from critics, with praise limited to the ensemble's acting and the visuals, but criticism of its writing, pacing, characterization, tone, music, and handling of mature subject matter. The critical consensus on review aggregator website Rotten Tomatoes reads, "Euphoria returns with less than the sum of its parts in a disjointed cavalcade of forced narratives that leave its talented cast stranded in the wind." The season has an overall approval rating of 44%, with an average rating of 5.8/10 based on 76 critical reviews. Using a weighted average, Metacritic assigned the season a score of 56 out of 100, based on 27 critics, which it describes as "Mixed or Average". Caryn James wrote for BBC News: "the show has lost its zeitgeisty edge. Euphoria has become a series with very little to say, none of it very audacious or compelling." David Opie of Digital Spy wrote, "Euphoria was a striking, standout coming-of-age drama, but the new season doesn't capture its magic. The show hasn't grown up in the same way that these kids supposedly have." Empire's Al Horner wrote, "some constants remain, the good and bad of Euphoria past. This is still a sumptuously-shot show, not to mention a well-acted one: Zendaya in particular is in formidable form once more, letting glints of sadness surface from beneath Rue's veneer of languid detachment. Less appealing is how the camera still hovers longingly over shots of its female characters' bodies, as one-by-one, Levinson's scripts nudge them into sex work and skimpy costumes.

To enhance sensitivity, the secondary capillary of the nano-DESI probe can be equipped with a nebulizer, which takes benefit of the Venturi effect, facilitating the aspiration of the liquid. This enables the secondary probe to be longer, while still maintaining stable electrospray, thereby simplifying the setup process. Moreover, it offers greater versatility in nano-DESI solvent selection, allowing water to be used as an extraction solvent. This expands the technique’s chemical coverage and enhances the customization of solvent components for selective extraction of polar compounds. Additionally, the capillaries can be integrated into a custom 3D-printed cassette, creating a convenient plug-and-play device.

If the chain is not being used for a high wear application (for instance if it is just transmitting motion from a hand-operated lever to a control shaft on a machine, or a sliding door on an oven), then one of the simpler types of chain may still be used. Conversely, where extra strength but the smooth drive of a smaller pitch is required, the chain may be "siamesed"; instead of just two rows of plates on the outer sides of the chain, there may be three ("duplex"), four ("triplex"), or more rows of plates running parallel, with bushings and rollers between each adjacent pair, and the same number of rows of teeth running in parallel on the sprockets to match. Timing chains on automotive engines, for example, typically have multiple rows of plates called strands. Roller chain is made in several sizes, the most common American National Standards Institute (ANSI) standards being 40, 50, 60, and 80. The first digits indicate the pitch of the chain in eighths of an inch, with the last digit being 0 for standard chain, 1 for lightweight chain, and 5 for bushed chain with no rollers. Thus, a chain with half-inch pitch is a No. 40 while a No. 160 sprocket has teeth spaced 2 inches apart, etc. Metric pitches are expressed in sixteenths of an inch; thus a metric No. 8 chain (08B-1) is equivalent to an ANSI No. 40. Most roller chain is made from plain carbon or alloy steel, but stainless steel is used in food processing machinery or other places where lubrication is a problem, and nylon or brass are occasionally seen for the same reason.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

How does SR9009 work?

It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.

Is SR9009 proven to improve human performance?

No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.

Is SR9009 approved for human use?

No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.

Network